This inventor holds 3 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignee: Ossianix, Inc.. Active years: 2021-2025.
Company Filing History:
Years Active: 2021-2025
Title: Innovations of Fabrizio Comper
Introduction
Fabrizio Comper is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of molecular medicine, particularly in the development of innovative therapeutic agents. With a total of 3 patents to his name, Comper's work focuses on overcoming challenges in drug delivery, especially across the blood-brain barrier.
Latest Patents
Comper's latest patents include groundbreaking inventions such as Anti-CD98hc VNARs for crossing the blood-brain barrier and type IV VNAR libraries. The first patent relates to CD98hc binding moieties that possess high specificity and the ability to cross the blood-brain barrier (BBB). These moieties can be utilized alone or as components in specific conjugates targeting amino acid transporter complexes formed with a light chain and CD98hc. The invention emphasizes VNAR single-chain antibodies derived from nurse sharks that bind to CD98hc, along with diagnostic and therapeutic methods for delivering biomolecules across the BBB. The second patent focuses on Type IV semi-synthetic VNAR libraries derived from shark VNARs, aimed at selecting binding moieties that specifically target molecular or cellular entities of interest.
Career Highlights
Throughout his career, Fabrizio Comper has worked with various companies, including Ossianix, Inc. and Spur Therapeutics Limited. His expertise in molecular medicine has positioned him as a key player in the development of targeted delivery systems for therapeutic agents.
Collaborations
Comper has collaborated with notable professionals in his field, including Krzysztof Bartlomiej Wicher and Pawel Stocki. These collaborations have further enhanced his research and development efforts in innovative drug delivery systems.
Conclusion
Fabrizio Comper's contributions to the field of molecular medicine and his innovative patents highlight his commitment to advancing therapeutic delivery methods. His work continues to pave the way for new solutions in treating conditions that require effective drug delivery across the blood-brain barrier.